S'abonner

Research and product development for Crimean–Congo haemorrhagic fever: priorities for 2024–30 - 08/11/24

Doi : 10.1016/S1473-3099(24)00656-X 
Amanda E Semper, DPhil a, , Janie Olver, PhD a, Jenny Warner, PhD b, Ana Cehovin, PhD c, Petra C Fay, PhD c, Peter J Hart, PhD c, Josephine P Golding, PhD c, Virginia Benassi, LLM e, Marie-Pierre Preziosi, MD e, Khdair Hazbar Razzaq Al-Asadi, FRCP f, Lucille H Blumberg, ProfMD g, José de la Fuente, ProfPhD h, Nazif Elaldi, ProfMD i, Tom Fletcher, PhD j, Pierre B H Formenty, DVM d, Mohammad Mehdi Gouya, ProfMD k, Stephan Günther, ProfMD l, Roger Hewson, ProfPhD b, m, Bushra Jamil, ProfFRCP n, Gary Kobinger, ProfMD o, Gülay Korukluoglu, ProfMD p, Laetitia Lempereur, PhD q, Gustavo Palacios, ProfPhD r, Anna Papa, ProfMD s, Natalia Pshenichnaya, ProfDSci t, u, Connie Schmaljohn, PhD v, Samba O Sow, ProfMD w, Hein Sprong, PhD x, Zati Vatansever, PhD y, Timothy J G Brooks, FRCPath a
a Epidemic and Emerging Infections Group, UK Health Security Agency, Salisbury, UK 
b Science Group, UK Health Security Agency, Salisbury, UK 
c Wellcome Trust, London, UK 
d Health Emergencies Programme, Geneva, Switzerland 
e World Health Organization, Geneva, Switzerland 
f Medical Department, Al-Hussein Teaching Hospital, Nasiriyah, Iraq 
g Department of Public Health and Outbreak Response, National Institute for Communicable Diseases, Johannesburg, South Africa 
h Group of Health and Biotechnology (SaBio), Instituto de Investigación en Recursos Cinegéticos IREC (Spanish National Research Council CSIC, University of Castilla-La Mancha UCLM, Autonomous Regional Government of Castile-La Mancha JCCM), Ciudad Real, Spain 
i Department of Infectious Diseases & Clinical Microbiology, Sivas Cumhuriyet University, Sivas, Türkiye 
j Liverpool School of Tropical Medicine, Liverpool, UK 
k Faculty of Public Health, Iran University of Medical Sciences & Health Services, Tehran, Iran 
l Department of Virology, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, Germany 
m Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK 
n Section of Infectious Diseases, Department of Medicine, AgaKhan University, Karachi, Pakistan 
o Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA 
p University of Health Sciences, Ankara Bilkent City Hospital, Ankara, Türkiye 
q Food and Agriculture Organization, Rome, Italy 
r Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA 
s Department of Microbiology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece 
t Central Research Institute of Epidemiology of Rospotrebnadzor, Moscow, Russia 
u Russian Medical Academy of Continuous Professional Education, Moscow, Russia 
v Integrated Research Facility, National Institute of Allergy and Infectious Diseases—National Institutes of Health, Fort Detrick, Frederick, MD, USA 
w Centre for Vaccine Development, Bamako, Mali 
x National Institute of Public Health & the Environment, Bilthoven, Netherlands 
y Department of Parasitology, Faculty of Veterinary Medicine, Kafkas University, Kars, Türkiye 

* Correspondence to: Dr Amanda E Semper, Epidemic and Emerging Infections Group, UK Health Security Agency, Salisbury SP4 0JG, UK Epidemic and Emerging Infections Group UK Health Security Agency Salisbury SP4 0JG UK
Sous presse. Épreuves corrigées par l'auteur. Disponible en ligne depuis le Friday 08 November 2024

Summary

Crimean–Congo haemorrhagic fever (CCHF) is a widely distributed and potentially fatal tick-borne viral disease with no licensed specific treatments or vaccines. In 2019, WHO published an advanced draft of a research and development roadmap for CCHF that prioritised the development and deployment of the medical countermeasures most needed by CCHF-affected countries. This Personal View presents updated CCHF research and development priorities and is the product of broad consultation with a working group of 20 leading experts in 2023–24. The strategic goals, milestones, and timelines have been revised and expanded to reflect scientific advances since 2019, including the identification of antibodies with therapeutic potential and the progression of four vaccine candidates through phase 1 clinical trials. This update emphasises the need for a One Health approach to manage CCHF, from integrated cross-sectoral surveillance to novel interventions that target ticks and their vertebrate hosts to reduce CCHF virus transmission to humans. The overarching vision for rapid diagnostics and specific therapeutics by 2028, followed by options to limit CCHF virus transmission and control disease by 2030, is deliberately ambitious and will only be achieved through coordinated international action from affected countries, funders, scientists, product developers, manufacturers, regulators, national authorities, and policy makers.

Le texte complet de cet article est disponible en PDF.

Plan


Crown Copyright © 2024  Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.